Medigen Biotechnology Cash Flow Reinvestment Rate
Medigen Biotechnology cash flow reinvestment rate. Medigen Biotechnology (3176) has a Cash Flow Reinvestment Rate of 0.26x as of December 2024, reinvesting NT$41.15 Million (capex NT$9.09 Million plus investments NT$-32.06 Million) from operating cash flow of NT$156.75 Million. Explore Medigen Biotechnology debt service capacity to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Medigen Biotechnology (2003–2024)
Cash flow reinvestment rate of Medigen Biotechnology from 2003 to 2024. Historical reinvestment intensity for Medigen Biotechnology across 5 annual periods. Explore Medigen Biotechnology capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Medigen Biotechnology Cash Flow Reinvestment Rate by Year (2003–2024)
Medigen Biotechnology cash flow reinvestment rate by year from 2003 to 2024. Year-by-year capital reinvestment analysis for Medigen Biotechnology. For the full cash flow conversion analysis, see 3176 operating cash flow.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 26.90x | NT$1.02 Billion | NT$37.92 Million | NT$58.68 Million | ▲ +1259.2% |
| 2021 | 1.98x | NT$1.02 Billion | NT$517.45 Million | NT$144.55 Million | ▼ -45.0% |
| 2015 | 3.60x | NT$1.06 Billion | NT$294.18 Million | NT$515.25 Million | ▲ +8952.2% |
| 2005 | 0.04x | NT$3.21 Million | NT$80.72 Million | NT$3.21 Million | ▲ +347.7% |
| 2003 | 0.01x | NT$3.96 Million | NT$445.46 Million | NT$3.96 Million | — |